You are here: Industry Insights > Gamaleya

News List

SII gets approval from DCGI to produce Sputnik V vaccine in India expresspharma
June 07, 2021
The firm has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology for developing Sputnik V at its licensed Hadapsar facility.
Russia’s Sputnik V Covid-19 vaccine shows 97.6% efficacy pharmaceutical-technology
April 20, 2021
The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) have reported that the Sputnik V Covid-19 vaccine showed a 97.6% efficacy.
EMA initiates rolling review of Russia’s Sputnik V vaccine for Covid-19 pharmaceutical-technology
March 05, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has initiated a rolling review of the Russian Covid-19 vaccine, Sputnik V.
Vaccine trials essential to evaluate effectiveness against new COVID-19 variants: GlobalData expresspharma
February 10, 2021
The largest proportion of the ongoing vaccine trials are now in Phase II (38.6 per cent) and Phase III (36.3 per cent), after Phase I studies dominated the earlier period of the pandemic.
Efficacy of Sputnik V against COVID-19 was reported at 91.6% worldpharmanews
February 03, 2021
The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announce that The Lancet, one of the world's ...
Russia to register COVID-19 vaccine on August 12 expresspharma
August 10, 2020
The vaccine is jointly developed by Gamaleya Research Institute and the Russian Defence Ministry.